Sucampo Pharmaceuticals’ subsidiary, Sucampo AG, has signed an exclusive global manufacturing and supply agreement with its development partner, R-Tech Ueno, Ltd. for clinical and commercial supplies of AMITIZA (lubiprostone) in most global markets.   Sucampo will receive a new, lower price for certain components of or finished product of lubiprostone globally, except for the U.S. and Canada until the license agreement with Takeda Pharmaceutical Co., Ltd. expires in December 31, 2020, and except...